Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Payables (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Payables readings, the most recent being $3.3 million for Q1 2026.

  • Quarterly Payables rose 118.51% to $3.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Mar 2026, up 118.51% year-over-year, with the annual reading at $1.5 million for FY2025, 56.91% up from the prior year.
  • Payables hit $3.3 million in Q1 2026 for DiaMedica Therapeutics, up from $1.5 million in the prior quarter.
  • Across five years, Payables topped out at $3.3 million in Q1 2026 and bottomed at $433000.0 in Q1 2022.
  • Average Payables over 5 years is $1.2 million, with a median of $926000.0 recorded in 2023.
  • The largest annual shift saw Payables surged 311.09% in 2023 before it crashed 59.78% in 2024.
  • DiaMedica Therapeutics' Payables stood at $734000.0 in 2022, then rose by 26.16% to $926000.0 in 2023, then increased by 1.51% to $940000.0 in 2024, then soared by 56.91% to $1.5 million in 2025, then soared by 123.25% to $3.3 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Payables are $3.3 million (Q1 2026), $1.5 million (Q4 2025), and $1.9 million (Q3 2025).